Low-dose Naltrexone, Curcumin, EGCG, Cisplatin- Integrative Ovarian Cancer Therapies

Share Button

“The objective of this study was to determine the effect on synergism in activity from the sequenced combinations of cisplatin (Cis) with curcumin (Cur) and epigallocatechin-3-gallate (EGCG) and LDN in the human ovarian cancer cell lines”

Ovarian cancer (OC) survivors often face multi-drug resistence. In effect, their OC stops responding to chemotherapy. Enter integrative therapies. According to the studies linked and excerpted below, cisplatin chemotherapy can be enhanced by curcumin, EGCG (green tea extract) and/or low-dose naltrexone (LDN).

Please don’t expect conventional oncology to know about, understand or prescribe evidence-based but NON-conventional integrative therapies such as combining ciplatin with LDN, Curcumin or EGCG.

To learn more about evidence-based non-conventional therapies please scroll down the page, post a question or comment and I will reply to you ASAP.

Hang in there,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:

Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells.

“Drug resistance remains an on-going challenge in OC chemotherapy. The objective of this study was to determine the effect on synergism in activity from the sequenced combinations of cisplatin (Cis) with curcumin (Cur) and epigallocatechin-3-gallate (EGCG) in the human ovarian cancer cell lines…

Addition of Cis 4 h before Cur and EGCG (0/4 h combination) produced the most synergistic outcomes in both the A2780 and A2780(cisR) cell lines. The cellular accumulations of platinum and platinum-DNA binding resulting from the 0/4 h combinations were greater as compared to the values using Cis alone, thus providing an explanation for the synergistic action. When sequenced combinations of Cis with Cur and with EGCG are applied to human ovarian A2780 and A2780(cisR) cancer cell lines, lower concentrations and shorter time gap between the two additions seem to produce a higher cytotoxic effect.”

Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.

“LDN combined with cisplatin alleviated the toxicity (e.g. weight loss) associated with cisplatin. LDN treatment upregulated the expression of the opioid growth factor (OGF, chemical term ([Met(5)]-enkephalin) and its receptor, OGFr. Previous tissue culture studies have reported that OGF is the only opioid peptide with antiproliferative activity on ovarian cancer cells, with OGF action mediated by OGFr. Thus, the common denominator of intermittent opioid receptor blockade by short-term NTX or LDN on OC proliferation and tumorigenesis recorded herein appears to be related to the OGF-OGFr axis. These preclinical data may offer a non-toxic and efficacious pathway-related treatment that can benefit patients with ovarian cancer.”

Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs

“Conclusion & future direction– The diagnosis of an advanced cancer, such as ovarian, means multi-modality therapy for most patients, which typically includes chemotherapy. Unfortunately, most chemotherapy is toxic not only to tumors, but also to healthy tissue. This adversely impacts quality of life both during and after therapy. In addition, most ovarian cancer patients will ultimately recur, and die of their disease. Current cancer research focuses on developing new therapies to both improve survival and decrease toxicity. Given the anti-cancer properties of curcumin we have focused on developing compounds based that are not restricted by poor bioavailability, limited solubility, and low potency…

Because of the complexity and variety of cancers found in the modern world, the idea of a “silver bullet” treatment or cure is unlikely to be found. However, the continued development of new therapies such as those described here will lead to improved survival and quality of life for cancer patients.”

Leave a Comment:

Add Your Reply